The relationship between obesity and adverse health is well established, but little is known about the contribution of DNA methylation to obesity-related health outcomes.
INTRODUCTION
Body mass is a complex trait that demonstrates a high degree of variance in the general population (1) . It is determined by the contribution of genetic, lifestyle, physiological and psychosocial factors, but together these factors fail to fully explain the inter-individual variation in the most widely used clinical measure of body mass, the body mass index (BMI; kg/m 2 ). Through recent advances in genomic analysis we are now able to test whether obesityrelated adverse health and disease may, in part, influence or be influenced by epigenetic changes, with the ultimate aim of more accurately predicting health outcomes.
Epigenetic mechanisms regulate gene expression through processes such as histone acetylation and DNA methylation (commonly the addition of a methyl group to a cytosine base in a cytosine-guanine rich sequence of DNA, or CpG), rather than changes to the DNA sequence itself. These modifications alter DNA accessibility and chromatin structure, determining whether a gene is active in a given cell at any one time (2) . Several recent studies have suggested links between BMI and DNA methylation: epigenome wide association studies (EWAS) have identified CpG sites associated with BMI at loci involved in lipid and lipoprotein metabolism, blood lipid levels, and inflammatory pathways (3, 4, 5) . Shah and colleagues (6) also found that methylation profiles associated with BMI accounted for 6.9% of the variance in BMI independently of genetic profiles (polygenic scores), in a group of 1,366 individuals form the Lothian Birth Cohort (LBC), which is the sample being studied in the present report.
A growing body of research examining associations between DNA methylation and health, assumes that exposures to adverse environmental stimuli induce epigenetic changes, which increase a genetically-mediated risk of disease (7) . If it is the case that differential methylation profiles contribute to the risk of adverse health, there is potential utility in using epigenetic data in the prediction of health outcomes. In the current study we test whether methylation profiles associate with adverse health outcomes. We examine 1) cross-sectional associations between an epigenetic score for BMI and health-related, cognitive, psychosocial and lifestyle outcomes and 2) whether epigenetic BMI score accounts for variance of these outcome variables independently of phenotypic BMI.
RESEARCH DESIGN AND METHODS

The Lothian Birth Cohort 1936
The Lothian Birth Cohort 1936 (LBC1936) is a group of individuals born in 1936 who took part in the 1947 Scottish Mental Survey when they were aged 11 years (8) . The survey tested the intelligence of 70,805 children in Scotland using the Moray House Test. 3,686 individuals who had taken the original test and were living in Edinburgh and the Lothians were contacted approximately 60 years later, of whom 1091 joined the LBC1936. Members of the LBC have provided a wealth of cognitive, neuropsychological, psychosocial, biological (including genomic and other 'omics) and neuroimaging data longitudinally as part of the LBC1936 study, which is ongoing (8, 9) . Recruitment and testing of the LBC1936 are described elsewhere (10) .
Ethics
Ethical permission for the LBC1936 was obtained from the Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and the Lothian Research Ethics Committee (LREC/2003/2/29). Written informed consent was obtained from all participants.
DNA Methylation
DNA methylation data were assessed in whole blood samples from the LBC1936 using the Illumina HumanMethylation450 BeadChip (Illumina Inc., San Diego, CA). Full details of sample preparation and methylation typing have been reported previously (11) . In brief, background correction was performed and quality control was used to remove probes with a low detection rate (P>0.01 for >5% of samples), low quality (manual inspection), low call rate (P<0.01 for <95% of probes), and samples with a poor match between genotypes and SNP control probes, with incorrectly predicted sex.
The regression weights for the LBC1936 (8) BMI epigenetic signature were derived from an independent cohort -Generation Scotland: the Scottish Family Health Study (GS; 13, 13) . Full details are provided in Appendix 1.
Phenotypic Data
Descriptive statistics for continuous outcome variables are presented in Table S1 . Binary variables relating to self-reported disease history included: high blood pressure, type 1 diabetes, type 2 diabetes, high cholesterol, cardiovascular disease, leg pain, poor blood circulation, stroke, neoplasm, health issues related to the thyroid, Parkinson's disease, arthritis and allergies. Data collection protocols for all variables are reported elsewhere (8, 14) .
Statistical Analyses
Linear regression models were used to investigate the relationship between the epigenetic BMI score and outcome variables. For each model, the R 2 statistic represents the proportion of variance in the outcome variable that can be accounted for by the epigenetic BMI score (see model 1), phenotypic BMI score (model 2) and both epigenetic BMI and phenotypic BMI scores together (model 3). To estimate the proportion of variance accounted for by these predictors without the effect of covariates, the R 2 statistic represents the difference between the and sex were included as covariates in all models. Height was included as an additional covariate in models for time taken to walk 6 metres, forced expiratory volume (lung function), and general physical health. The models are as follows: Logistic regressions were conducted for self-reported disease history variables as these had binary outcomes (disease/no disease). Similar to the models above, logistic regressions were carried out for each variable to test whether epigenetic BMI, phenotypic BMI, and an additive model combining epigenetic BMI score and phenotypic BMI, were associated with disease history. For all analyses a Bonferroni corrected level of significance was used (p<0.05/n_tests=0.0011). Analyses were carried out in R version 3.4.0 (15) .
Sensitivity analysis
For variables that associated with epigenetic BMI, we carried out further sensitivity analyses, by including a polygenic score for BMI (for details see Appendix 2) as a predictor in the additive model with epigenetic BMI score and phenotypic BMI (model 4).
Model 4: variable of interest ~ epigenetic BMI score + phenotypic BMI + genetic BMI score + age at time of testing + sex
RESULTS
This study included 903 individuals (female n=446, 49.4%), with a mean age of 69.5 years.
Epigenetic BMI score is associated with outcomes related to physical health, biomarkers of metabolic syndrome, crystallised intelligence and social deprivation
Linear regressions were carried out to test whether the epigenetic score for BMI generated in GS was associated with health-related, cognitive, psychosocial, and lifestyle outcomes in the LBC1936. Only associations with a p value <0.0011 (i.e. after Bonferroni correction) are presented here -full results are presented in Table 1 .
Epigenetic BMI was strongly associated with phenotypic BMI (p<2x10 -16 ) and accounted for 10% of its variation. Increases in epigenetic BMI score also correlated with poorer performance on all other physical health variables, but only correlations with 6 metre walk time, lung function and general physical health remained after correction for multiple comparisons. As epigenetic BMI score increased by 1 SD, time taken to walk 6 metres increased by 0.1 seconds (p=1.7x10 -05 , R 2 = 0.02), forced expiratory volume decreased by 0.1 litres (p=6.3x10 -08 , R 2 =0.02) and general physical health decreased by 0.13 SDs (p=4x10 -08 , R 2 =0.02). Epigenetic BMI score demonstrated negative correlations with blood biomarker variables: HbA1c (p=2x10 -14 , R 2 = 0.06), C-reactive protein (p=5.9x10 -4 , R 2 = 0.01), triglycerides (p<2x10 -16 , R 2 = 0.09), high density lipoprotein cholesterol (HDL; p<2x10 -16 , R 2 =0.08) and HDL ratio (HDL cholesterol/total cholesterol; p=1.6x10 -07 , R 2 =0.03). Finally, epigenetic BMI score was negatively associated with crystallised intelligence as measured by the National Adult Reading Test (NART; p=3x10 -04 , R 2 =0.01), Scottish Index of Multiple Deprivation score (p=3.9x10 -05 , R 2 = 0.02), physical health-related quality of life (p=5.1x10 -5 , R 2 = 0.02) and self-reported physical activity (p=1.5x10 -04 , R 2 = 0.02) Variables that associated with epigenetic BMI were included in additive linear regression models, with both epigenetic and phenotypic BMI score as predictors. These models showed that epigenetic and phenotypic BMI explain partially independent proportions of the variance.
This pattern was most striking for biomarker variables related to metabolic syndrome -additive models that demonstrated associations with these biomarkers are presented in figure 1.
Figure 1: Plot of R 2 statistics from linear regression analyses in which epigenetic BMI, phenotypic BMI and epigenetic + phenotypic BMI respectively associated with biomarker variables at p> 0.0011.
The plots demonstrate the general pattern observed, with the additive model accounting for a greater proportion of variation than models including epigenetic BMI score only, or phenotypic BMI only.
A polygenic score for BMI did not increase R 2 of additive models
Tables S2 and S3 present results of linear and logistic regression models in which a polygenic score for BMI was included as a predictor variable alongside epigenetic BMI score and phenotypic BMI. In these additive models, a polygenic BMI score did not associate with any of the variables tested.
A linear regression model with both epigenetic BMI score and polygenic BMI score, polygenic BMI showed a strong association with phenotypic BMI (p<2x10 -16 ) and both predictors accounted for 18% of variation in phenotypic BMI. 
Epigenetic BMI score is associated with self-reported disease history
DISCUSSION
Using DNA methylation data, we constructed an epigenetic score for BMI to test its association with health, cognitive and lifestyle outcomes in an independent dataset, the LBC1936. We found that epigenetic BMI score is associated with poorer physical health (time taken to walk 6 metres, lung function and general physical health), higher levels of HbA1c, blood derived Creactive protein, triglycerides and HDL cholesterol (all biomarkers for metabolic syndrome), poorer crystallised intelligence, lower physical health-related quality of life, a lower selfreported physical activity and greater social deprivation. Our analysis also showed that epigenetic BMI score is associated with self-reported type 2 diabetes (a finding previously reported by Wahl et al., who identified diabetes via clinical diagnosis, or HbA1c ≥ 6.5% (3)), cardiovascular disease and high blood pressure: health outcomes for which obesity is a major risk factor.
In almost all analyses, phenotypic BMI accounted for a greater proportion of variance of outcome variables than epigenetic BMI, but phenotypic and epigenetic BMI scores together accounted for a greater proportion of variance still. This additive effect suggests that epigenetic and phenotypic BMI scores account for at least partially independent proportions of variance.
It is possible that some these partially independent associations are driven by correlations between the CpG probes used to create the epigenetic BMI score and the outcome variables of interest. This could mean that our epigenetic score for BMI is capturing the downstream effects of obesity, such as biological processes associated with poor metabolic health, which phenotypic BMI (a more 'blunt' measure of metabolic health) does not account for directly.
We found that an epigenetic score for BMI accounted for 10% of the variance in phenotypic BMI, a higher proportion than that reported by Shah et al. (6) , whose epigenetic BMI score accounted for 6.9% of the variance in phenotypic BMI in the LBC1936. This improvement could be due to our larger discovery sample (5,200 vs 1,366) , and/or because weights for our epigenetic BMI score were calculated using a single regression model, with BMI residuals as the outcome and CpGs as predictors, rather than separate models for each CpG predictor (see Appendix 1) . Shah et al also found that an epigenetic BMI score improved phenotype prediction when combined with a genetic score for BMI from 8% to 14% (6) . By including both an epigenetic and a polygenic score for BMI as predictors in our linear regression model, we improved the proportion of variance in phenotypic BMI explained from 10% to 18%.
However, our polygenic score for BMI did not associate with any variables when included alongside epigenetic BMI score and phenotypic BMI as predictors in regression models. In the majority of these models, polygenic BMI score had little effect; associations between epigenetic BMI score and outcome variables remained, particularly for physical health and biomarker variables. It could be the case that the epigenetic BMI score encompasses the interaction between the polygenic BMI score and outcome variables implicated in biological processes related to obesity (as opposed to cognitive or lifestyle variables). If this is the case, there appears to be little benefit in the inclusion of a polygenic score for BMI alongside epigenetic BMI and phenotypic BMI scores in assessing association with biological and physical health-related variables.
Our results demonstrate that BMI (and epigenetic BMI) is associated with obesity-related adverse health and thus, is a clinically-relevant metric for measuring body mass. However, the BMI has been criticised due to its assumption that a low body mass equates to metabolic health.
Dvorak et al. (16) found that BMI failed to distinguish between healthy individuals and individuals who were metabolically obese, but of normal weight despite differences in total fat mass, body fat percentage, subcutaneous fat and visceral abdominal adiposity. It has also been shown that waist to height ratio (WHtR) and waist/height 0.5 (WHT.5R) are better predictors of whole body fat percentage and visceral adipose tissue mass than BMI (17) . Despite this, the BMI continues to be widely used in clinical settings. A development upon this study would be to test whether an epigenetic score based on WHtR or WHT.5R can further increase the proportion of variance in obesity-related outcomes explained by epigenetic BMI.
A limitation of this study is the inability to make strong directional inferences; it is impossible to tell whether differential DNA methylation is a mediator of the causal disease pathway, or occurs in response to disease processes. Recent progress has been made in this area using a Mendelian Randomisation approach (18) A recent study by Richmond et al. (22) combined several of these methods to detect causality between BMI and methylation at HIF3A (a gene linked to metabolism and obesity, and associated with adiposity in multiple EWAS (23, 24)), including bidirectional Mendelian randomisation analysis, longitudinal analysis of HIF3A methylation, and analysis of association between maternal pregnancy BMI and HIF3A methylation in offspring at birth (using cord blood). Results across each method indicated that a higher BMI causally influenced higher HIF3A methylation, suggesting that alterations in DNA methylation are a downstream effect of obesity. Further longitudinal studies and studies of naturalistic interventions are needed to elucidate the direction of causal association between obesity and DNA methylation, and to provide mechanistic insight into the pathophysiology of obesity-related disease.
We have demonstrated that an epigenetic score for BMI is associated with poorer physical health and health-related quality of life, biomarkers for metabolic syndrome and major diseases for which obesity is a major risk factor, social deprivation, physical inactivity and lower crystallised intelligence. An epigenetic score for BMI based on DNA methylation increased the amount of variance in health outcomes accounted for by phenotypic BMI score alone, demonstrating the value in using epigenetic information for constructing more accurate risk prediction for obesity-related biomarkers, health conditions and disease.
